PCSK9 inhibition: ready for prime time in CKD?
Lowering LDL cholesterol reduces the risk of atherosclerotic vascular disease in a wide range of patients with chronic kidney disease, with no evidence of a threshold below which further reductions no longer reduce risk. Statins safely lower LDL cholesterol, but novel inhibitors of proprotein conver...
Descripción completa
Detalles Bibliográficos
| Autores principales: |
Mafham, M,
Haynes, R |
|---|
| Formato: | Journal article
|
|---|
| Lenguaje: | English |
|---|
| Publicado: |
Elsevier
2018
|
|---|